Future Directions and Frontline Integration Strategies

Dr. Patel shifts focus from R/R to frontline settings, highlighting menin inhibitor investigation in newly diagnosed AML as exciting development areas. He asks about anticipated outcomes from ongoing studies examining intensive chemotherapy plus menin inhibitor or azacitidine-venetoclax plus menin inhibitor combinations in upfront NPM1-mutated AML treatment. Dr. Arana Yi describes combination strategy interests focusing on response assessment including remission achievement, response depth evaluation, and response durability assessment.

NPM1-mutated disease offers excellent disease monitoring capabilities through measurable residual disease (MRD) strategies using reverse transcriptase polymerase chain reaction. Menin inhibitors potentially provide pathways for disease elimination beyond morphological standpoints, achieving deep residual disease elimination. Effective frontline treatment reduces future relapsed disease likelihood, potentially enabling disease cure discussions without transplant consideration for specific patient groups. KOMET-007 results showing high remission rates, MRD negativity, and important remission duration demonstrate menin inhibitor frontline setting roles.

Dr. Patel emphasizes intensive chemotherapy patient goals of curing NPM1-mutated disease ideally without allogeneic transplant. Upfront response deepening through menin inhibitor addition with prospective benefit confirmation represents exciting developments. Intensive chemotherapy plus ziftomenib data and intensive chemotherapy plus revumenib high MRD negativity rates presented at ASH by Alice Mims at Ohio State University provide encouraging results. Lesser intensity approaches through HMA plus venetoclax plus menin inhibitor studies continue, noting NPM1-mutated disease sensitivity to HMA plus venetoclax doublets. Triplet therapy may deepen responses, with important questions regarding toxicity offset versus deeper response survival benefits awaiting phase 3 study confirmation of triplet versus azacitidine-venetoclax backbone survival advantages.